MAP2K7 and colorectal carcinoma: On the basis of data from this phase Ib trial, the combination of anti-PD-L1 immunotherapy and an MEK inhibitor represents the first potential immune-modifying therapy that might increase response to immunotherapy in patients with MSS mCRC who comprise 95% of CRC patients [189, 190].